Aerosol Particle Size: The Core Metric That Decides Nebulizer Clinical Performance and Channel Competitiveness

For distributors, brand owners, and private-label operators planning a compressor nebulizer program, specification sheets tend to look alike — until one figure is checked: aerosol particle size. Two units can run reliably, produce a visible mist, and pass every test, yet still deliver most of the dose to the mouth and throat rather than to the bronchi or alveoli the prescription targets. That gap shows up as weak channel feedback, higher complaint rates, and a price that does not stick.

For buyers, aerosol particle size is not a footnote. It is a specification that must be read, compared, and verified before an OEM/ODM program is committed.

Why Particle Size Decides Whether a Nebulizer Works

The lungs' branching structure acts as a natural aerodynamic filter: the deeper the target, the smaller the particle must be.

• particles larger than about 5 µm deposit in the oropharynx and upper airways, where they are swallowed rather than absorbed;

• particles of roughly 2–5 µm are suited to the lower airways and bronchi — the target zone for asthma and COPD management;

• particles of roughly 1–2 µm reach the alveolar region;

• particles below about 0.5–1 µm are largely exhaled before depositing.

That is why the standards framework treats particle size as a primary performance characteristic. Under ISO 27427 (Annex C for output rate, Annex D for particle size distribution), manufacturers are expected to disclose the distribution — typically as MMAD and respirable fraction — alongside output rate and residual volume.

The Four Numbers Behind the Specification

MMAD: Mass Median Aerodynamic Diameter

MMAD is the aerodynamic diameter at which 50% of the aerosol mass is contained in droplets of that size or smaller. Aerodynamic — not geometric — diameter is the correct measure, because it accounts for both size and density. For lower-airway therapy, an MMAD in the 1–5 µm band is the clinically useful range, with roughly 2–4 µm commonly reported for well-performing compressor systems.

Respirable Fraction

MMAD alone can mislead: a distribution can sit at 3 µm while placing most of its mass above 5 µm. The respirable fraction — the cumulative percentage of aerosol mass below 5 µm — closes the gap. It states how much of the emitted dose is in a range capable of reaching the lower airways.

GSD: Geometric Standard Deviation

GSD describes how tightly the distribution clusters around the median. ISO 27427 testing commonly reports MMAD with GSD, and specifications frequently target GSD ≤ 2.0.

Residual Volume

Residual volume is the liquid left in the medication cup when nebulization stops. It does not change particle size, but it changes how much of the prescribed dose ever becomes aerosol. High residual volume quietly reduces delivered dose and extends treatment time — felt by patients as "the machine never finishes" and by channels as accessory and complaint volume.

Where the Dose Goes

The practical reading is simple: a nebulizer's job is not to make mist, but to place mass in the 1–5 µm band. Everything else is emitted dose that never reaches the target.

What Determines Particle Size in a Compressor Nebulizer

• Jet and venturi geometry — the primary lever on median size.

• Baffle design — converts a coarse spray into a respirable distribution.

• Compressor airflow and pressure — output rate and particle size move together, so pump and cup must be validated as a matched pair.

• Cup design and fill volume — ISO 27427 figures are tied to a stated fill volume and breathing profile.

• Drug formulation — suspensions carry undissolved particles whose size can dominate the distribution.

• Operating mode — continuous versus breath-actuated designs deliver different effective doses from the same nominal specification.

Two suppliers can both claim "MMAD ≤ 5 µm" and still deliver meaningfully different respirable fractions at different fill volumes with different drugs. The specification only becomes comparable when the test conditions are stated alongside the number.

Particle Size as a Commercial Specification

How Joytech Supports Buyers on Aerosol Performance

Joytech Healthcare manufactures home healthcare devices for global distribution from a compressor-focused core that has shipped to more than 150 countries. The compressor nebulizer range — covering adult, pediatric, portable, and themed SKUs across the NB series — sits inside an OEM/ODM program structure that supports branding, packaging, and configuration for distributor and brand partners.

For buyers who need aerosol performance to be part of the commercial case, Joytech provides:

l Compressor nebulizer development under ISO 13485 with documented process control, using medical-grade components and BPA-free materials

l Internal testing capability covering particle size distribution, alongside EMC, electrical safety, and usability evaluation

l Validation of compressor pump and medication cup as a matched system, so output rate and particle distribution are optimized together rather than independently

l Certification coverage including CE MDR (EU 2017/745), Canada Medical Device Licence, and MHRA registration, with select models carrying FDA 510(k) clearance

l 100+ R&D specialists supporting specification alignment and regulatory documentation

l An accessory ecosystem across nebulizer kits — medication cups, adult / child / infant masks, mouthpieces, and air tubing

l Production across 260,000+ sqm of manufacturing footprint, supported by 100+ patents

Market Outlook: The Mist Is Not the Specification

As respiratory care moves toward more documented, more regulated, and more professionalized channel structures, the products that hold their position will be the ones whose aerosol performance can be stated rather than demonstrated by appearance. Aerosol particle size is a specification that can be verified, compared, and built into a defensible product claim — but only with a manufacturer who measures it, documents it, and can repeat the result at production scale.

Partner with Us

To discuss a nebulizer OEM/ODM program, request category documentation, or arrange technical evaluation samples, contact sale14@sejoy.com.

FAQ

Q1: What is a good MMAD for a nebulizer?

For lower-airway therapy such as asthma and COPD management, an MMAD in the 1–5 µm range is generally regarded as the clinically useful band, with approximately 2–4 µm commonly reported for well-performing compressor systems. Pair MMAD with the respirable fraction and GSD — a median alone does not show how much of the dose is actually useful.

Q2: Why does respirable fraction matter more than MMAD alone?

MMAD states where the middle of the distribution sits, not how much of the dose is useful. Respirable fraction gives the proportion of emitted aerosol mass below 5 µm — the portion capable of reaching the lower airways. Two nebulizers with identical MMAD figures can differ substantially in respirable fraction, and that difference translates into delivered dose and clinical response.

Q3: Does particle size change with fill volume or medication?

Yes. Distribution and output rate are measured against a stated fill volume and breathing profile, and performance at other fill volumes is not automatically equivalent. Suspensions carry undissolved particles whose size influences the distribution differently from a solution. Compare suppliers only with the fill volume, test drug, and test method stated.